For those patients who have not been able to stop this<unk>  on their own, doctors have been working to discover a treatment that will work for everyone. One treatment that Schenck and Mahowald studied consisted of psychotherapy combined with "environmental manipulation". This was usually done separately from the weight-reducing diets. However, during this study only 10 percent of the patients were able to lose more than one third of their initial excess weight, which was not a viable percentage. In addition, they reported that many of the patients experienced "major depression" and "severe anxiety" during the attempted treatments. This was not one of the most successful attempts to help those with<unk> . However, Dr. R. Auger reported on another trial treatment where patients were treated utilizing pramipexole. Those conducting the treatment noticed how the<unk>  median motor activity was decreased, as was assessed by actigraphy, and individual progress of<unk>  quality was reported. Nevertheless, Augur also said, "27 percent of subjects had RLS (restless legs syndrome, a condition known to respond to this medication), and number and duration of waking episodes<unk>  to<unk>  behaviors were unchanged." Encouraged by the positive response verified in the above-mentioned trial treatment, doctors and psychiatrists conducted a more recent study described by Auger as "efficacy of topiramate an antiepileptic drug associated with weight loss in 17 consecutive patients with<unk> ." Out of the 65 percent of patients who continued to take the medication on a regular basis, all confirmed either considerable development or absolute remission of "night-eating" in addition to "significant weight loss" being achieved. This has been one of the most effective treatments discovered so far, but many patients still suffered from<unk> . Therefore, other treatments were sought after. Such treatments include those targeted to associated<unk><unk> s with the hope that it would play an essential part of the treatment process of<unk> . In Schenck and Mahowald's series, combinations of cardibopa/L-dopa, codeine, and clonazepam were used to treat five patients with RLS and one patient with somnambulism and PLMS (periodic limb movements in<unk> . These patients all were suffering from<unk>  as well as these other<unk> s, and they all experienced a remission of their<unk>  as a result of taking these drugs. Two patients with OSA (obstructive<unk>  apnea) and<unk>  also reported as having a "resolution of their symptoms with nasal continuous positive airway pressure (nCPAP) therapy." Clonazepam monotherapy was also found to be successful in 50 percent of patients with simultaneous somnambulism. Dopaminergic agents such as monotherapy were effective in 25 percent of the<unk>  subgroup. Success with combinations of dopaminergic and opioid drugs, with the occasional addition of sedatives, also was found in seven patients without associated<unk><unk> s. In those for whom opioids and sedatives are relatively contraindicated (e.g., in those with histories of substance abuse), two case reports were described as meeting with success with a combination of bupropion, levodopa, and trazodone. Notably, hypnotherapy, psychotherapy, and various behavioral techniques, including environmental manipulation, were not effective on the majority of the patients studied. Nevertheless, Auger argue that behavioral strategies should complement the overall treatment plan and should include deliberate placement of food to avoid indiscriminate wandering, maintenance of a safe<unk>  environment, and education regarding proper<unk>  hygiene and stress management. Even with their extensive studies, Schenck and Mahowald did not find the success as Auger found by treating his patients with topiramate.
Nocturnal sleep-related eating disorder
Night eating syndrome
Binge eating disorder
Binge eating
Bulimia nervosa
Hedonic hunger
Recurrent brief depression
Compulsive buying disorder